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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.06.039Background: Vascular calcification is a common pathologic and precisely regulated
process involving bone-associated proteins such as osteopontin. In this study, we
investigated mechanisms by which recombinant human vascular endothelial growth
factor 165 protects the arterial wall from severe vascular remodeling, including calci-
fication, a newly discovered biologic action of vascular endothelial growth factor.
Methods: In a rabbit model of thoracic aortic end-to-end anastomosis that simulates
cardiovascular intervention, recombinant human vascular endothelial growth factor
165 at a dose of 0.75 g (n  19) or albumin (control; n  19) was delivered
intraluminally and on the serosal surface. Animals were killed, and aortic tissue was
evaluated by Western blotting, immunohistochemistry, and immunofluorescence at
4, 8, and 24 hours; 1 week; and 1 month after surgery.
Results: All controls revealed extensive aortic medial calcification at 1 month, whereas
calcification was significantly reduced or absent with vascular endothelial growth factor
treatment. Compared with controls, vascular endothelial growth factor treatment re-
sulted in an earlier infiltration of macrophages in the vessel media (at 8 hours: 5.7 2.3
macrophages per high-power field in control vs 32.1  7.5 in vascular endothelial
growth factor–treated aortas; P  .001), whereas controls showed an increase in
macrophages starting at 1 week (24.1  6.9 vs 4.3  1.8; P  .001). Osteopontin
expression was transiently increased and detected in macrophages and endothelial cells
in vascular endothelial growth factor–treated vessels, and adventitial microvascular
density was significantly increased by 1 week (9.5  0.43 vs 25.0  1.3; P  .001).
Conclusions: Our data suggest that exogenous vascular endothelial growth factor is
capable of increasing adventitial angiogenesis and shifting macrophage infiltration and
osteopontin expression in the media to an earlier time point, thereby promoting prompt
repair and diminishing vascular remodeling and calcification after acute vascular injury.
Vascular remodeling, defined as any enduring change in the size orcomposition of a blood vessel, is a common disease affecting thecardiovascular system (with or without arterial calcification) inboth children and adults. It is associated with numerous adverseevents, including myocardial infarction, stroke, and hyperten-sion.1-3 Calcification frequently accompanies vascular remodeling
even when the disease is in its early stages of development.2 The mechanisms
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CSPunderlying vascular calcification are unclear, and therapeu-
tic interventions to halt this disease process are limited. We
recently described severe vascular remodeling with fibrosis,
calcification, and chondroid metaplasia in a new model of
thoracic aortic end-to-end anastomosis in rabbits.4 Locally
applied recombinant human vascular endothelial growth
factor (rhVEGF) was capable of reducing dystrophic medial
calcification in this model. However, the mechanisms re-
sponsible for this new biological action of VEGF are un-
known.
Earlier reports regarded vascular calcification as a pas-
sive degenerative process, but there is now strong evidence
suggesting that arterial calcification is an actively regulated
process with striking similarities to normal mineralization
of bone and cartilage.5,6 Similar to normal bone, several
bone-associated proteins have been found in vascular cal-
cification,5,7-9 including osteopontin (OPN), a multifunc-
tional arginine/glycine/aspartic acid phosphoprotein.10 OPN
has been observed at sites of calcification in human athero-
sclerotic plaques and in calcified aortic valves,7,9 suggesting
that OPN may play a regulatory role in pathologic calcifi-
cation. In atherosclerosis and calcific valves, macrophages
seemed to be the major source of OPN, although both
endothelial cells and vascular smooth muscle cells
(VSMCs) are known to synthesize OPN.7,9,11 When exog-
enous OPN was added to a model of VSMC calcification, it
was associated with hydroxyapatite crystals, and calcifica-
tion was inhibited.12 Several stimuli regulate the expression
of OPN, including inflammatory mediators and hypoxia.13
Because hypoxia regulates the expression of the angiogenic
inducer VEGF,14 a mediator involved in the recruitment and
activation of monocyte-macrophages,15,16 we postulated
that VEGF may, directly or indirectly, regulate OPN ex-
pression in the arterial wall in the setting of acute vascular
injury and, thus, alter vascular healing.
Methods
Study Protocol
A total of 38 male New Zealand White rabbits (9 weeks old;
weight, 2.2-2.8 kg) underwent aortic end-to-end anastomosis as
previously described.4 Briefly, the thoracic aorta was dissected
free just below the left subclavian artery, and after proximal and
distal crossclamping, a 10-mm ring of thoracic aorta was resected.
The end-to-end anastomosis was performed with running 7-0
polypropylene suture (Ethicon, Somerville, NJ). The distance be-
tween the crossclamps after resection was approximately 14 mm.
Treatment existed of applying either the rhVEGF165 (5 g/mL;
R&D Systems, Minneapolis, Minn) or the vehicle phosphate-
buffered saline/0.1% albumin as control to the intraluminal surface
while the anastomosis was performed (10 minutes’ exposure time)
and after crossclamp release to the serosal surface (1 mm beyond
the crossclamp site, 10 minutes’ exposure time) by using a 1-mL
syringe with a 27-gauge needle (Sherwood Medical, St Louis,
Mo). A total volume of 0.15 mL of VEGF was split between the
intraluminal surface and the adventitial surface and applied by
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make contact with the vessel wall. rhVEGF has been used in
several animal models.17,18 The rabbits were allowed to recuperate
and maintained under standardized conditions with a regular day/
night cycle (12/12 hours), free access to water, and standard rabbit
diets (Prolab Hi-Fiber 5P25; PMI Nutrition International, St Louis,
Mo). All studies were performed with approval of the Animal Care
and Use Committee of Children’s Memorial Institute of Education
and Research and in accordance with the Guide for the Care and
Use of Laboratory Animals (National Institutes of Health publica-
tion No. 85-23, revised 1996).
Tissue Harvest and Histology
At 4 hours (n  4), 8 hours (n  8), 24 hours (n  8), 1 week (n 
10), and 1 month (n 8), equal numbers of control and VEGF-treated
rabbits were killed with intravenous pentobarbital (150 mg/kg). The
heart, aortic arch, and thoracic aorta were immediately excised and
gently flushed with saline. For histologic examination, the proximal
segment of the anastomotic area (9 mm) was divided in 3 equal
sections: the anastomosis itself, the portion including the proximal
crossclamp, and the aortic wall between the anastomosis and the
crossclamp. Parallel sections from each group were assessed, and a
mean score was calculated for each aorta by using values obtained
from all 3 segments. The tissue did not require decalcification. The
tissue was fixed in 10% formalin overnight and embedded in paraffin,
and 4-m sections were placed on a glass slide and stained with
hematoxylin & eosin, elastica van Gieson, and Von Kossa. The
degree of fibrosis, calcification, and chondrocyte metaplasia was
graded 1 to 4 (1 none; 4 severe) by a pathologist (S.E.C.) blinded
to treatment regimen, as previously described.4 The aorta adjacent to
the anastomotic suture line up to and including the distal crossclamp
area was snap-frozen in liquid nitrogen and stored at 80°C.
Immunohistochemistry
Histologic sections of rabbit aortas were immunostained with
antibodies directed against OPN (1B20; Assay Designs, Inc, Ann
Arbor, Mich), macrophages (HAM 56; DAKO), von Willebrand
factor–related antigen (DAKO, Carpinteria, Calif), or cartilage
oligomeric matrix protein (Kamiya Biomedical Co, Seattle, Wash).
Sections were incubated with an avidin-biotin peroxidase–
conjugated secondary antibody and counterstained with hematoxylin
or incubated with a fluorescence-conjugated (fluorescein isothiocya-
nate and phycoerythrin) secondary antibody. Control tissues were run
in parallel to verify the specificity of the immunoreactivity where cell
populations were known to be positive as well as negative (OPN/
kidney, macrophage/lymph node, endothelial cell/uninjured aorta,
chondrocyte/trachea, and calcium/bone marrow). Negative controls
were performed by omitting the primary antibody. Quantification of
macrophages was performed at the different time points by counting
5 random high-power fields (hpf) per aorta by 2 independent observ-
ers blinded to the treatment regimen.
Western Blot Analysis
Frozen aortas were homogenized in radioimmunoprecipitation
(RIPA) buffer. Protein concentration was determined with bicin-
choninic acid protein assay reagent (Bio-Rad, Hercules, Calif).
Equal protein (25 g per lane) was loaded into the wells of a 10%
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Psodium dodecyl sulfate-polyacrylamide gel, subjected to electro-
phoresis under reducing conditions, and blotted onto Hybond-C
nitrocellulose membranes (Amersham, Arlington Heights, Ill). Af-
ter blocking with 5% nonfat dry milk/Tris-buffered saline (pH
8.0)/1% Tween-20, the membrane was subsequently incubated
with primary anti-OPN antibody (1:50; Assay Designs) and per-
oxidase-conjugated secondary anti-mouse immunoglobulin G (1:
1000; Santa Cruz Biotechnology, Santa Cruz, Calif). Signals were
developed with Luminol reagent for Western blotting (Santa
Cruz). Identically loaded Coomassie-stained gels confirmed equal
protein loading. Molecular size standards (Bio-Rad) and recombi-
nant OPN (30 ng per lane) were included as controls. Band
intensities were quantified by densitometry with equalization to
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TABLE 1. Histologic characteristics of the arterial wall at
1 month
Histologic feature
Control
(mean  SEM)
VEGF treated
(mean  SEM) P value
Fibrosis 3.1 0.5 1.5  0 .007
Calcification 3.6 0.5 1.7  0.6 .004
Chondroid metaplasia 3.5 0.6 1.7  0.6 .004
VEGF, Vascular endothelial growth factor.E
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CSPThe number of endothelial cell–lined vessels identified by anti–
von Willebrand factor staining in the adventitia was counted in 5
random hpf per histologic section. Values are expressed as mean
SEM. Data were analyzed by using the unpaired 2-tailed Student
t test and analysis of variance.
Results
Effect of VEGF on Vascular Remodeling
Gross examination of the control aortic specimens revealed
marked changes at the anastomotic suture site and the
adjacent aortic wall near the former crossclamp area, with
more extensive plaques by 1 month (Figure 1, A). In con-
trast, the suture line and the adjacent aorta of VEGF-treated
specimens remained linear, without gross evidence of cal-
cification (Figure 1, E). At earlier time points, control and
VEGF-treated aortas appeared grossly similar. However,
marked differences between the control and VEGF-treated
groups were observed histologically as early as 24 hours
after surgery. Control aortas at 1 month after surgery con-
firmed the gross findings, and cross sections from the suture
site and the adjacent tissue revealed a bandlike region of
dystrophic calcification in the media in all specimens (Fig-
ure 1, B). The calcium deposition, demonstrated by Von
Kossa staining (Figure 1, D) was so severe that it disrupted
the integrity of the arterial wall, including the elastica. As
observed previously, islands of mature-appearing cartilage
(chondroid metaplasia; inset, Figure 1, B) identified by
anti– cartilage oligomeric matrix protein staining (Figure 1,
C) were often in direct continuity with the pathologic cal-
cification.4 In contrast, VEGF-treated aortas at 1 month
revealed mild focal calcification with only a small island of
chondrocytes at the anastomotic site, whereas tissue adja-
cent to this site showed no dystrophic calcification or chon-
droid metaplasia (Figure 1, F-H). The endothelial cell layers
remained intact, and there was only mild fibrosis in the
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Figure 2. Local rhVEGF significantly increased adventitial angio-
genesis by 1 week. *P < .001 compared with the control group.
Results are mean  SEM.adventitia, with occasional extension into the media. When
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groups were graded for degree of fibrosis, calcification, and
chondroid metaplasia, the VEGF-treated aortas demon-
strated significantly less disease (Table 1).
Adventitial Angiogenesis
In control specimens, the adventitia of the anastomotic area
revealed acute inflammatory infiltrates as early as 8 hours
after surgery, and the inflammatory process increased by 1
week. In the same group, adventitial neovascularization was
limited to the foci of inflammation by 24 hours, with a mean
adventitial microvascular density (MVD) of 4.2  0.6 cell-
lined vessel per hpf. The level of angiogenesis increased
twofold by 1 week (mean MVD, 9.5  0.4 cell-lined vessel
per hpf) and remained increased at 1 month (7.7  0.4
cell-lined vessel per hpf). The VEGF-treated aortas showed
only focal adventitial inflammation; however, several ag-
gregates of capillaries were observed in the adventitia even
in noninflamed regions within 24 hours (5.0 0.5 cell-lined
vessel per hpf). By 1 week, the inflammatory infiltrates
remained focal and were predominantly mononuclear cells.
The adventitia showed a striking fivefold increase in MVD
(25.0  1.3 cell-lined vessel per hpf), significantly above
the mean MVD of the 1-week control group (Figure 2; P 
.001). However, the heightened angiogenesis was only tem-
porary in the VEGF-treated group as the adventitial MVD
decreased to 6.9  0.7 cell-lined vessel per hpf by 1 month.
Macrophage Infiltration
Because VEGF is known to recruit macrophages in other
circumstances,15,16 we determined whether there was an
alteration in the macrophage population in the aortic media
of the VEGF-treated and control groups. The pattern of
macrophage infiltration in the aortic walls was significantly
different between groups. When macrophages were counted
in aortas harvested at 4, 8, and at 24 hours, the control aortas
revealed only rare macrophages in the media (Figure 3, A
and B), whereas the VEGF-treated group showed an early
infiltration of macrophages in the media by 4 and 8 hours
(mean number of macrophages per hpf: 5.7  0.4 in control
vs 32.1  1.8 in VEGF-treated aortas; P  .001; Figure 3,
D and G), and the macrophages persisted at 24 hours (4.4
0.3 in control versus 17.4  1.3 in VEGF-treated aortas;
P  .001, Figure 3, E and G). At 1 week and beyond, the
media of control aortas began to show an increase in mac-
rophages, whereas the inflammatory cell infiltrate in the
VEGF-treated group seemed to resolve (24.1  1.8 in
control vs 4.3  0.2 in VEGF-treated aortas; P  .001;
Figure 3, G). At 1 month, the aortic media of the control
animals continued to demonstrate more inflammatory cells
(Figure 3, C), unlike the rare macrophages noted in the
VEGF-treated aortas (Figure 3, F).
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POPN Expression
OPN has been implicated in the pathogenesis of calcifica-
tion5,7-9,12,19 and has been shown to be induced by VEGF in
vitro.20 To determine whether alteration in OPN expression
was a target of topical VEGF treatment, we investigated the
time course of expression of OPN protein by Western
blotting. At time 0, Western blotting revealed a low level of
OPN in the aorta (Figure 4, A). At 8 hours after surgery,
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CSPtected in the adventitia only, and this staining increased in
both groups at 24 hours after surgery (data not shown).
Similar to the pattern observed by Western analysis, adven-
titial OPN expression remained increased in control aortas
at 1 month, whereas it returned almost to time 0 levels with
VEGF treatment. In the VEGF-treated group, the time
course of OPN expression in the media paralleled that of
macrophage infiltration. In this group, there was a rapid
increase in OPN, with strong staining detected in the lumi-
nal endothelial cells and in the immediate subjacent tissue
by 4 hours after injury (Figure 5, D), whereas the control
group showed mild staining in a rare endothelial cell (Figure
5, A). By 24 hours, the VEGF-treated group had OPN
localized to the entire media (Figure 5, E) in infiltrating
macrophages (inset, Figure 5, E). Immunofluorescence dou-
ble staining revealed that 40% of macrophages in the vessel
media expressed OPN (data not shown). This was in con-
trast to the weak endothelial staining and faint medial stain-
ing observed in the control group (Figure 5, B). The differ-
ence in OPN staining between groups was most apparent at
1 week. At this time point, in the VEGF-treated group, OPN
staining was retained by the endothelial cells, and the media
was predominantly negative, with only focal positivity at
the interface between the media and adventitial layers of the
aorta (Figure 5, F). In contrast, the control specimens
showed intense staining for OPN in the media and adven-
Figure 4. Representative Western blots showing an ea
panel, A) when compared with controls (left panel, A)
densitometric analysis. Data are mean  SEM; n  3
the control group.titia and only focal positivity in endothelial cells (Figure 5,
778 The Journal of Thoracic and Cardiovascular Surgery ● ApriC). This high level of OPN expression persisted at 1 month
after surgery.
Discussion
The endothelial cell–specific mitogen VEGF has drawn
widespread attention for its therapeutic value of stimulating
angiogenesis in cardiovascular disease.21,22 However, de-
pending on the physiologic context or experimental model
used, rhVEGF or VEGF gene transfer can have beneficial,
adverse, or no effects at all on the vessel wall. In a model of
neointimal VSMC hyperplasia in which the endothelium is
not initially damaged, VEGF gene therapy strikingly inhib-
ited neointimal VSMC hyperplasia,23 whereas, when the
endothelium is denuded in the balloon arterial injury model,
local intravascular administration of VEGF accelerated re-
endothelialization, thus leading to marked reduction in in-
timal thickening.24 Another more controversial study
showed that in apolipoprotein E–deficient mice, a single
intraperitoneal dose of rhVEGF stimulated macrophage in-
filtration in the atherosclerotic plaque and actually enhanced
its progression.17,25 We recently observed a new biological
action of VEGF to trigger suppression of pathologic vascu-
lar calcification and chondroid metaplasia.4 Here we present
several potential mechanisms underlying the ability of
VEGF to protect the arterial wall from severe remodeling
after aortic end-to-end anastomosis as performed to repair a
peak in OPN protein level in VEGF-treated aorta (right
ecombinant OPN (positive control). B, Corresponding
als per time point and group. *P < .05 compared withrlier
. , R
animcoarctation of the aorta. One possible mechanism is related
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Pto the ability of VEGF to induce endothelial cell prolifera-
tion.14 VEGF-treated aortas demonstrated an increase in
adventitial angiogenesis, as indicated by significantly higher
MVD. The neovascularization was seemingly unrelated to
the degree of inflammation and was transient. It is possible
that this brief exposure to an angiogenic stimulus resulting
in neovascularization could help to overcome acute hypoxia
associated with the aortic end-to-end anastomosis.26
In addition to the activity of VEGF on the adventitia, our
results point to 2 other possible mechanisms in another
segment of the arterial wall, the media. The first observation
involves earlier recruitment of macrophages, and the second
is related to earlier expression of OPN at the site of injury
(Figure 6). Previous studies have found that VEGF can act
as a chemotactic factor for monocyte-macrophages through
its receptor Flt-1 (VEGF receptor-1).15,16 We found that
VEGF shifted the infiltration of macrophages in the arterial
media to an earlier postinjury time point than in the control
aortas. This earlier response may be important in wound
healing, but it may also suppress calcific deposits, because
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Figure 5. OPN immunostaining in control (A-C) and VEG
indicate OPN positivity. Inset in (E) demonstrates an Othe macrophages have been reported to clear the injured
The Journal of Thoraciaortic wall of dead cell bodies that can then act as nucleating
structures for calcification.27 Moreover, mononuclear cells
might undergo differentiation toward osteoclast-like cells,
as proposed by Doherty and colleagues,28 and thus restrict
calcification.
OPN has been noted in areas of dystrophic calcification
as atherosclerotic plaques and calcified aortic valves,7,9 and
both in vitro12 and in vivo19 studies have suggested that the
upregulation of OPN in areas of dystrophic calcification is
an attempt to limit vascular calcification. OPN has also been
found in lesions after arterial injury, thus suggesting that it
plays a pathologic role in intimal hyperplasia.29 These ap-
parently opposing actions of OPN on the injured arterial
wall made it difficult to predict whether OPN would act as
an inducer or inhibitor of vascular remodeling. Our data
indicated that the time course of OPN expression after
arterial injury may be crucial for determining its course of
action. OPN was substantially upregulated in the VEGF-
treated aortas, and, similar to the timing of the macrophages,
OPN expression occurred much earlier than in the control
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25µm
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ated (D-F) aortas at different times points. Arrowheads
macrophage. L, Lumen.F-treaortas (Figure 6). Both macrophages and endothelial cells
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CSPseemed to be sources of OPN after injury. Control aortas
had sustained expression of OPN and persistent macrophage
infiltration. One or both of these factors could impair proper
wound healing.
Our findings in this experimental model suggest that
VEGF can protect vessels from pathologic remodeling by
stimulating adventitial angiogenesis, recruiting macro-
phages, and upregulating vascular OPN levels in the early
phase after arterial injury. Further studies are needed to
determine whether OPN alone is sufficient to diminish
pathologic vascular calcification. Moreover, these findings
suggest that current protocols testing VEGF as an agent for
therapeutic angiogenesis in ischemic tissue may have an-
other unexpected therapeutic benefit: reduction of the cal-
cific deposits that often complicate vascular stenoses.
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